A Phase Ib/III Study to Evaluate the Efficacy and Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer Who Failed Standard of Care Therapies
NCT04851613 · ACTIVE NOT RECRUITING · Phase 3
We track 1 ClinicalTrials.gov studies led by Laekna Limited. The portfolio skews toward Phase 3 (1 trials).
1 clinical trials sponsored by Laekna Limited.
| Phase | Trials | Distribution |
|---|---|---|
| Phase 3 | 1 | 100% |
Laekna Limited currently sponsors 1 clinical trials tracked on ReadTheTrial. These span Phase 3.
Laekna Limited conducts research across multiple therapeutic areas. Browse the trial listings for details.
Check the trial listings below for current recruitment status. Trial recruitment status can change frequently.